Sangamo Therapeutics (SGMOQ) Net Income towards Common Stockholders (2010 - 2025)

Sangamo Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$37.4 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 59.94% year-over-year to -$37.4 million; the TTM figure through Dec 2025 stood at -$122.9 million (down 23.89% YoY), while the FY2025 annual figure was -$122.9 million, down 25.52% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$37.4 million, down from -$34.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $21.1 million in Q1 2023, with the low at -$114.5 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$43.6 million (2022), against an average of -$42.5 million.
• The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders sank 3062.33% in 2021, then surged 148.05% in 2023.
• Sangamo Therapeutics' Net Income towards Common Stockholders stood at -$37.5 million in 2021, then plunged by 38.53% to -$51.9 million in 2022, then declined by 16.08% to -$60.3 million in 2023, then surged by 61.2% to -$23.4 million in 2024, then plunged by 59.94% to -$37.4 million in 2025.
• Business Quant data shows SGMOQ's Net Income towards Common Stockholders at -$37.4 million in Q4 2025, -$34.9 million in Q3 2025, and -$20.0 million in Q2 2025.